Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial

Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., on behalf of the study investigators·2012·Clinical & Experimental Allergy

Abstract

Summary: Background: Increased numbers of neutrophils are reported in the airways of patients with severe asthma. It is not clear if they contribute to the lack of control and severity. There are currently no strategies to investigate this by decreasing neutrophil numbers in the airways. Objective: To investigate the safety and efficacy of SCH 527123, a selective CXCR 2 receptor antagonist, in patients with severe asthma and increased number of neutrophils in sputum. Methods: In a randomized, double‐blind, parallel study, patients with severe asthma and sputum total cell count < 10 × 10 6/g and neutrophils > 40% were randomized to SCH 527123, 30 mg daily PO (n = 22) or placebo (n = 12) for 4 weeks. Primary end‐points were safety and change in sputum and blood neutrophil counts. Secondary end‐points were change in asthma control questionnaire (ACQ) score, minor and major exacerbations, spirometry and sputum neutrophil activation markers. Results: The SCH 527123 caused a mean reduction of 36.3% in sputum neutrophil percentage compared to a 6.7% increase in the placebo arm (P = 0.03). The mean absolute neutrophil count in blood was reduced by 14% at the end of 4 weeks, but recovered by the 5th week. There were no differences in the overall rates of adverse events among the groups. There were fewer mild exacerbations (1.3 vs. 2.25, P = 0.05) and a trend towards improvement in the ACQ score (mean difference between groups of 0.42 points, P = 0.053). No statistically significant changes were observed in forced expiratory volume in 1 s (FEV 1), sputum myeloperoxidase, IL 8 or elastase. Conclusions: The SCH527123 is safe and reduces sputum neutrophils in patients with severe asthma. Clinical Relevance: This new treatment provides an opportunity to investigate the role of neutrophils in severe asthma with potential clinical benefits. Larger studies of longer duration are needed to evaluate the impact on other outcomes of asthma including exacerbations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2012.04014.x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 333

Metadata

Authors
Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., & on behalf of the study investigators
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2012-06-15
Volume
42
Issue
7
Pages
1097-1103
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W1992347215
Cited by
333
References
27
FWCI
20.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial. https://app.cochat.ai/papers/10.1111/j.1365-2222.2012.04014.x
The paper
Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., & on behalf of the study investigators. (2012). Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2012.04014.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.